Treatment of chronic pain in older people: Evidence-based choice of strong-acting opioids

Drugs and Aging

Volumn 29, Issue 8, 2012, Pages 615-625

  Van Ojik, Annette L ^a,b   Jansen, Paul A F ^a   Brouwers, Jacobus R B J ^a,c   Van Roon, Eric N ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; TAPENTADOL;

ARTICLE; CANCER PAIN; CHRONIC PAIN; CONFUSION; CONSTIPATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HALLUCINATION; HUMAN; LOW BACK PAIN; NAUSEA; OSTEOARTHRITIS; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; TORSADE DES POINTES; VASODILATATION; VOMITING;

AGED; ANALGESICS, OPIOID; CHRONIC PAIN; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FRAIL ELDERLY; HUMANS;

EID: 84864152061     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11632620     Document Type: Article

References (50)

1. Gianni W, Ceci M, Bustacchini S, et al. Opioids for the treatment of chronic non-cancer pain in older people. Drugs Aging 2009; 26 Suppl. 1: 63-73
2. Moore RA, Straube S, Eccleston C, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analysis. Pain 2012; 153: 265-8
3. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171 (7): 686-91
4. Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol Toxicol 1992; 32: 271-302
5. Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004; 39: 1731-8
6. BowieMW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother 2007; 5 (3): 263-303
7. HämmerleinA,DerendorfH, LowenthalDT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet 1998; 34 (1): 49-64
8. Huisman-Baron M, van der Veen L, Jansen PAF, et al. Criteria for drug selection in frail elderly persons. Drugs Aging 2011; 28 (5): 391-402
9. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151 (9): 1825-32
10. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice: a post-marketing surveillance study in 13179 patients. Cur Med Res Opin 2005; 21 (8): 1147-56
11. Gianni W, Madaio AR, Geci M, et al. Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old. J Pain Symptom Manage 2011; 41: 707-14
12. Yu SY, Sun Y, Zhang HC, et al. Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients [abstract]. Zhongua Yi Xue Za Zhi 2003 Nov; 83 (22): 1931-5
13. Vorsanger G, Xiang J, Biondi D, et al. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients. Pain Res Manage 2011; 16 (4): 245-51
14. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009; 25 (5); 1095-104
15. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7 (5): R1046-50
16. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003; 4 (5): 231-56
17. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63 (1): 17-32
18. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Cur Med Res Opin 2004; 20 (9): 1419-28
19. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained- release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997 May; 13 (5): 254-61
20. Hartrick GT, Rozek RJ. Tapentadol in pain management, a m-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011; 25 (5): 359-70
21. Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther 2010; 27 (10): 714-30
22. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010; 112: 226-38
23. Mucci-LoRusso P, Berman BS, Silverstein PT, et al. Controlled- release oxycodone compared with controlledrelease morphine in the treatment of cancer pain: a randomized, double blind, parallel-group study. Eur J Pain 1998; 2: 239-49
24. Kalso E, Vainio A. Morphine and oxycodone in the management of cancer pain. Clin Pharmacol Ther 1990 May; 47(5): 639-46
25. Maddocks I, Somogyi A, Abott F, et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996 Sep; 12 (3): 182-9
26. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Cur Med Res Opin 2009; 25 (9): 2133-50
27. Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56: 93-6
28. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging 2010; 27 (5): 417-33
29. Goodarzi M, Narasimhan RR. The effect of large-dose intrathecal opioids on the autonomic nervous system. Anesth Analg 2001; 93: 456-9
30. Harris JD. Management of expected and unexpected opioidrelated side effects. Clin J Pain 2008; 24 (4): S8-13
31. Andrews CM, Krantz MJ, Wedam EF, et al. Methadoneinduced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J 2009; 16 (3): 210-7
32. van Roon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Safety 2005; 28 (12): 1131-9
33. Li Y, Kantelip JP, Gerritsen-van Schieveen P, et al. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008; 12 (2): 109-24
34. Baxter K, editor. Stockleys drug interactions. 9th ed. London: Pharmaceutical Press, 2010
35. Nucynta (tapentadol) immediate release oral tablets: US prescribing information. Raritan: Ortho-McNeil-Janssen Pharmaceuticals Inc., 2008
36. Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid- IR) in young and elderly subjects. Proc West Pharmacol Soc 2001; 44: 79-80
37. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52: 137-47
38. Lugo RA, Satterfiel KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19 (4): 13-24
39. Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev 2007; (4): CD003971
40. Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990 Mar; 64 (3): 276-82
41. Bö ger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006; 20 Suppl. 1: s17-23
42. Durnin C, Hind ID, Wickens MM, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc 2001; 44: 81-2
43. Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010; 10 (5): 428-50
44. Vadivelu N, Hines RL. Management of chronic pain in the elderly: focus on transdermal buprenorphine. Clin Interv Aging 2008; 3 (3): 421-30
45. Plosker GL. Buprenorphine 5, 10 and 20 mg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs 2011; 71 (18): 2491-509
46. Holdsworth MT, Forman WB, Killilea TA, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology 1994; 40: 32-7
47. Vaughan C. Development and implementation of a process to ensure safe use of morphine sulfate extended-release liposome injection. Am J Health Syst Pharm 2008; 65 (5): 458-61
48. Chou R, Fanciullo GJ, Fine PG, et al. American Pain Society - American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10 (2): 113-30
49. Barber JB, Gibson SJ. Treatment of chronic non-malignant pain in the elderly. Drug Saf 2009; 32 (6): 457-74
50. McLachlan AJ, Bath S, Naganathan V, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. Brit J Clin Pharmacol 2011; 71 (3): 351-64